{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:53:03Z","timestamp":1764186783263,"version":"3.46.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tierarztl Prax Ausg K Kleintiere Heimtiere"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Gegenstand und Ziel H\u00e4mangiosarkome (HSA) der Milz beim Hund sind\n                    hochmaligne mesenchymale Tumoren, die eine hohe Metastasierungsneigung\n                    aufweisen. Auch mit adjuvanter Chemotherapie nach der Splenektomie liegen die\n                    medianen \u00dcberlebenszeiten i.d.R. bei lediglich 5\u20138 Monaten. Ziel\n                    dieser Studie war, anhand einer prospektiven randomisierten Doppelblindstudie\n                    nach der Splenektomie die Wirksamkeit einer adjuvanten dendritischen\n                    Zelltherapie nach der PetBioCell-Methode zu \u00fcberpr\u00fcfen. Zudem\n                    wurden m\u00f6gliche unerw\u00fcnschten Wirkungen dieser Therapie\n                    evaluiert.<\/jats:p>\n                  <jats:p>Material und Methoden Einundzwanzig Hunde mit histologisch nachgewiesenem,\n                    nicht-metastasiertem HSA der Milz (Stadium I und II) nach Splenektomie wurden in\n                    die Studie inkludiert. Zehn Hunde erhielten die dendritische Zelltherapie, 11\n                    Hunde bekamen ein Placebo injiziert. Die Applikation erfolgte nach\n                    Herstellerangaben in den ersten 3 Monaten monatlich, anschlie\u00dfend alle 3\n                    Monate bis zum Tod der Patienten. Die \u00dcberlebenszeiten sowie die\n                    unerw\u00fcnschten Wirkungen beider Gruppen wurden verglichen.<\/jats:p>\n                  <jats:p>Ergebnisse Der Follow-up aller Patienten reichte bis zur Euthanasie oder\n                    Versterben aufgrund von Metastasen. Ein Patient aus der Gruppe mit der\n                    dendritischen Zelltherapie wurde aufgrund einer Prostatitis euthanasiert, dieser\n                    hatte die l\u00e4ngste \u00dcberlebenszeit (668 Tage). Ein Hund aus der\n                    Placebo-Gruppe \u00fcberlebte 448 Tage nach Splenektomie. Die mediane\n                    \u00dcberlebenszeit betrug bei der dendritischen Zelltherapie-Gruppe 74 Tage,\n                    bei der Placebo-Gruppe 126 Tage. Statistisch zeigte sich in der Tumor-freien\n                    Zeit (t(18) = 1,4, p = 0,911) und der \u00dcberlebenszeit\n                    (t(19) = \u20130,094, p = 0,463) zwischen den beiden Gruppen\n                    kein Unterschied. Alle unerw\u00fcnschten Wirkungen waren in der\n                    Therapiegruppe mild und selbstlimitierend, auch in der Placebo-Gruppe wurde von\n                    \u00e4hnlichen milden unerw\u00fcnschten Wirkungen berichtet.<\/jats:p>\n                  <jats:p>Schlussfolgerung und klinische Relevanz Die Immuntherapie mit autologen,\n                    unreifen und ungeprimten dendritischen Zellen nach der PetBioCell-Methode zeigte\n                    beim kaninen H\u00e4mangiosarkom der Milz in dieser Studienpopulation keine\n                    nachweisbare Wirksamkeit hinsichtlich der Tumor-freien Zeit und\n                    \u00dcberlebenszeit.<\/jats:p>","DOI":"10.1055\/a-2197-9906","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T18:33:03Z","timestamp":1701887583000},"page":"394-402","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvante Behandlung des caninen H\u00e4mangiosarkoms der Milz mit\n                    der autologen dendritischen Zelltherapie \u2013 eine prospektive,\n                    placebokontrollierte, randomisierte Doppelblindstudie"],"prefix":"10.1055","volume":"51","author":[{"given":"Amalia","family":"Reck","sequence":"additional","affiliation":[{"name":"Abteilung Onkologie, Tierklinik Hofheim, Hofheim"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Gedon","sequence":"additional","affiliation":[{"name":"Abteilung Onkologie, Tierklinik Hofheim, Hofheim"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kessler","sequence":"additional","affiliation":[{"name":"Abteilung Onkologie, Tierklinik Hofheim, Hofheim"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"ref1","first-page":"250","article-title":"Splenic masses in dogs. Part 1: Epidemiologic, clinical characteristics as well\n                    as histopathologic diagnosis in 249 cases (2000-2011)","volume":"40","author":"N Eberle","year":"2012","journal-title":"Tierarztl Prax Ausg K Kleintiere Heimtiere"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2460\/javma.251.5.559","article-title":"Evaluation of clinical and histologic factors associated with survival time in\n                    dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant\n                    chemotherapy: 30 cases (2011\u20132014)","volume":"251","author":"A S Moore","year":"2017","journal-title":"J Am Vet Med Assoc"},{"key":"ref3","first-page":"651","article-title":"Das H\u00e4mangiosarkom der Milz \u2013 Klinische Aspekte bei 52\n                    Hunden","volume":"25","author":"M Kessler","year":"1997","journal-title":"Tier\u00e4rztl Prax Ausg K Kleintiere Heimtiere"},{"key":"ref4","first-page":"967","article-title":"Canine visceral hemangiosarcoma treated with surgery alone or surgery and\n                    doxorubicin: 37 cases (2005\u20132014)","volume":"59","author":"K Batschinski","year":"2018","journal-title":"Can Vet J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cvsm.2019.04.009","article-title":"Histiocytic Sarcoma and Hemangiosarcoma Update","volume":"49","author":"C Mullin","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2460\/javma.1988.193.06.706","article-title":"Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic\n                    hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985)","volume":"193","author":"C Prymak","year":"1988","journal-title":"J Am Vet Med Assoc"},{"key":"ref7","first-page":"6","article-title":"Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and\n                    hemoperitoneum requiring a transfusion: 71 cases (2003\u20132005)","volume":"232","author":"T N Hammond","year":"2008","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5326\/15473317-34-5-417","article-title":"Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by\n                    splenectomy alone: 32 cases (1991-1993)","volume":"34","author":"C Wood","year":"1998","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1002\/vetr.585","article-title":"Canine and feline haemangiosarcoma","volume":"189","author":"M A Griffin","year":"2021","journal-title":"Vet Rec"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2460\/javma.1985.186.01.56","article-title":"Canine hemangiosarcoma: retrospective analysis of 104 cases","volume":"186","author":"N O Brown","year":"1985","journal-title":"J Am Vet Med Assoc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"G K Ogilvie","year":"1996","journal-title":"J Vet Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5326\/JAAHA-MS-5954","article-title":"VAC Protocol for Treatment of Dogs with Stage III Hemangiosarcoma","volume":"49","author":"F J Alvarez","year":"2013","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1939-1676.2007.tb01958.x","article-title":"Clinical and pharmacokinetic characteristics of intracavitary administration of\n                    pegylated liposomal encapsulated Doxorubicin in dogs with splenic\n                    hemangiosarcoma","volume":"21","author":"K Sorenmo","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12917-015-0446-1","article-title":"Maintenance therapy with toceranib following doxorubicin-based chemotherapy for\n                    canine splenic hemangiosarcoma","volume":"11","author":"H L Gardner","year":"2015","journal-title":"BMC Vet Res"},{"key":"ref15","first-page":"773","volume-title":"Miscellaneous tumors: Hemangiosarcoma. In: Withrow SJ, Vail DM, Page RL. Withrow\n                    and MacEwen's Small Animal Clinical Oncology","author":"C Mullin","year":"2019"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59\n                    cases (1997-2004)","volume":"231","author":"S E Kim","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with\n                    or without adjuvant chemotherapy: 208 cases (2001\u20132012)","volume":"247","author":"K M Wendelburg","year":"2015","journal-title":"J Am Vet Med Assoc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1939-1676.2000.tb02262.x","article-title":"Treatment of canine Hemangiosarcoma: 2000 and Beyond","volume":"14","author":"C A Clifford","year":"2000","journal-title":"J Vet Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1892\/0891-6640(2004)18<209:eatoad>2.0.co;2","article-title":"Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine\n                    hemangiosarcoma","volume":"18","author":"K U Sorenmo","year":"2004","journal-title":"J Vet Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cvsm.2019.04.010","article-title":"Cancer Immunotherapies","volume":"49","author":"P J Bergman","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1084\/jem.180.1.83","article-title":"Proliferating dendritic cell progenitors in human blood","volume":"180","author":"N Romani","year":"1994","journal-title":"J Exp Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is\n                    maintained by granulocyte\/macrophage colony-stimulating factor plus\n                    interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"179","author":"F Sallusto","year":"1994","journal-title":"J Exp Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5326\/JAAHA-MS-6540","article-title":"Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine\n                    Splenic Hemangiosarcoma","volume":"53","author":"A Matsuyama","year":"2017","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2460\/javma.258.6.630","article-title":"Retrospective evaluation of thrombocytopenia and tumor stage as prognostic\n                    indicators in dogs with splenic hemangiosarcoma","volume":"258","author":"A R Masyr","year":"2021","journal-title":"J Am Vet Med Assoc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jsap.12796","article-title":"Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?","volume":"59","author":"J P Bray","year":"2018","journal-title":"J Small Anim Pract"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1892\/0891-6640(2007)21[113:eoantv]2.0.co;2","article-title":"Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma","volume":"21","author":"L W U\u2019Ren","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating\n                    antigen-presenting cells critical for T cell immunity","volume":"26","author":"M L Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"A Gardner","year":"2020","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic Cell\u2013Based Immunotherapy: State of the Art and Beyond","volume":"22","author":"K F Bol","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"12339","DOI":"10.3390\/ijms222212339","article-title":"Dendritic cells and cancer immunotherapy: The adjuvant effect","volume":"22","author":"S Nava","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"S Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41417-019-0080-3","article-title":"Dendritic cell vaccination plus low-dose doxorubicin for the treatment of\n                    spontaneous canine hemangiosarcoma","volume":"26","author":"V Konduri","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1016\/s0264-410x(02)00382-1","article-title":"A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of\n                    human monocyte-derived dendritic cells: implications for immunotherapy","volume":"20","author":"A W Lee","year":"2002","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","article-title":"Dendritic cell based tumor vaccination in prostate and renal cell cancer: a\n                    systematic review and meta-analysis","volume":"6","author":"A Draube","year":"2011","journal-title":"PloS One"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"641307","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on from Sipuleucel-T: New dendritic cell vaccine strategies for prostate\n                    cancer","volume":"12","author":"SI M Sutherland","year":"2021","journal-title":"Front Immunol"},{"key":"ref40","first-page":"12","article-title":"Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma\n                    patients is determined by their maturation state","volume":"63","author":"IJ M De Vries","year":"2003","journal-title":"Cancer Res"}],"container-title":["Tier\u00e4rztliche Praxis Ausgabe K: Kleintiere \/ Heimtiere"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2197-9906.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:49:06Z","timestamp":1764186546000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2197-9906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,12,6]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2197-9906","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1434-1239","2567-5842"],"issn-type":[{"type":"print","value":"1434-1239"},{"type":"electronic","value":"2567-5842"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}